Anticorps Polyclonaux Purifiés par Affinité à l’Antigène

Anti-Human IP-10 (CXCL10)

0 ReviewsSubmit a Review

Product Details

Catalogue Number: 500-P93

Source: Polyclonal Rabbit

Preparation: Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant hIP-10. Anti-Human IP-10 specific antibody was purified by affinity chromatography employing immobilized hIP-10 matrix.

Immunogen: E.coli derived Recombinant Human IP-10 (CXCL10) (PeproTech catalog# 300-12)

Sandwich ELISA: To detect hIP-10 by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech’s Biotinylated Anti-Human IP-10 (500-P93Bt) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIP-10.

Anti-Human IP-10 (CXCL10) Sandwich ELISA

Western Blot: To detect hIP-10 by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIP-10 is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.

Anti-Human IP-10 (CXCL10) Western Blot Reduced Anti-Human IP-10 (CXCL10) Western Blot Unreduced

Note:

Additional applications tested on a lot-to-lot basis. Please contact Technical Support for more information.

crossreactivity:
Country Of Origin: USA

Not for human use.

Research Interest

product.subtitle.recentcitations

First Author
Rabquer, B J
Title
Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis.
Citation
Arthritis research & therapy; 13(1) pgR18
PubMed Id
First Author
Kao, J
Title
Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease.
Citation
Circulation; 107(15) pg1958-61
PubMed Id
First Author
Izhak, L
Title
Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner.
Citation
Journal of immunology (Baltimore, Md. : 1950); 184(2) pg1092-101
PubMed Id